Shilpa Medicare Limited has informed the Exchange about Ex-parte ad-interim injunction order regarding pharmaceutical drug product
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Delhi High Court has issued an ex-parte ad-interim injunction on December 29, 2025, restraining Shilpa Medicare along with its material subsidiary Shilpa Pharma Lifesciences and wholly owned subsidiary FTF Pharma from manufacturing, selling, exporting, or supplying any pharmaceutical product containing Ruxolitinib or Ruxolitinib Salts API, citing alleged infringement of Patent No. IN269841 (a JAK Inhibitor compound). A court-appointed Local Commissioner also visited the company's premises to inspect records and stock registers; the company says it fully cooperated. Shilpa clarifies that the product in question was used only for research purposes and that there is no financial impact from this order. The company is evaluating legal options, including filing responses or appeals, and says normal business operations remain unaffected.
Short-term impact appears limited as the company claims no financial exposure and operations are running as usual, but the patent dispute could become a longer-term overhang if the injunction is upheld or expanded. Retail investors should watch for updates on the company's legal response and any future revenue contribution from Ruxolitinib-related products.